342 related articles for article (PubMed ID: 10673700)
1. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
5. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
6. A comparison of related donor peripheral blood and bone marrow transplants: importance of late-onset chronic graft-versus-host disease and infections.
Anderson D; DeFor T; Burns L; McGlave P; Miller J; Wagner J; Weisdorf D
Biol Blood Marrow Transplant; 2003 Jan; 9(1):52-9. PubMed ID: 12533742
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: a single-center experience.
Bacigalupo A; Zikos P; Van Lint MT; Valbonesi M; Lamparelli T; Gualandi F; Occhini D; Mordini N; Bregante S; Berisso G; Vitale V; Sessarego M; Marmont AM
Exp Hematol; 1998 May; 26(5):409-14. PubMed ID: 9590657
[TBL] [Abstract][Full Text] [Related]
8. Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.
Singhal S; Powles R; Treleaven J; Horton C; Swansbury GJ; Mehta J
Bone Marrow Transplant; 1996 Dec; 18(6):1049-55. PubMed ID: 8971372
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
12. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
[TBL] [Abstract][Full Text] [Related]
14. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB
Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090
[TBL] [Abstract][Full Text] [Related]
15. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
16. Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors.
Miyamura K; Hamaguchi M; Taji H; Kanie T; Kohno A; Tanimoto M; Saito H; Kojima S; Matsuyama T; Kitaori K; Nagafuji K; Sato T; Kodera Y
Bone Marrow Transplant; 2000 Mar; 25(5):545-8. PubMed ID: 10713633
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Gaziev J; Sodani P; Polchi P; Andreani M; Lucarelli G
Ann N Y Acad Sci; 2005; 1054():196-205. PubMed ID: 16339666
[TBL] [Abstract][Full Text] [Related]
18. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
20. Do corticosteroids add any benefit to standard GVHD prophylaxis in allogeneic BMT?
Ancín I; Ferrá C; Gallardo D; Peris J; Berlanga J; Gonzalez JR; Virgili N; Grañena A
Bone Marrow Transplant; 2001 Jul; 28(1):39-45. PubMed ID: 11498742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
